CLCD Colucid Pharmaceuticals, Inc.

CoLucid Pharmaceuticals, Inc. (Nasdaq:CLCD), a biopharmaceutical company that is developing lasmiditan oral tablets for the acute treatment of migraine in adults, with or without aura, announced today it will provide a corporate overview at the 28th Annual Piper Jaffray Healthcare Conference, being held on November 29-30 in New York City.

28th Annual Piper Jaffray Healthcare Conference
Date:		Wednesday, November 30
Time:		1:00 pm Eastern Time
Location:		The Lotte New York Palace Hotel, Holmes I Room
Webcast:		http://edge.media-server.com/m/p/cfdngzft

About CoLucid Pharmaceuticals, Inc.CoLucid is developing lasmiditan oral tablets for the acute treatment of migraine headaches in adults and intravenous lasmiditan for the acute treatment of headache pain associated with migraine in adults in emergency room and other urgent care settings.

CONTACT
Thomas Mathers
Chief Executive Officer
CoLucid Pharmaceuticals, Inc.
(857) 285-6494

Hans Vitzthum
Managing Director
LifeSci Advisors, LLC.
(212) 915-2568